Cargando…

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults

PURPOSE: A non-randomised, open-label, Phase I safety and immunogenicity dose-finding study to assess the safety and immunogenicity of the candidate TB vaccine Modified Vaccinia virus Ankara expressing Antigen 85A (MVA85A) from Mycobacterium tuberculosis (MTB) in healthy adult volunteers previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pathan, Ansar A., Minassian, Angela M., Sander, Clare R., Rowland, Rosalind, Porter, David W., Poulton, Ian D., Hill, Adrian V.S., Fletcher, Helen A., McShane, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424417/ https://www.ncbi.nlm.nih.gov/pubmed/22789508 http://dx.doi.org/10.1016/j.vaccine.2012.06.084

Ejemplares similares

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A
por: Griffiths, Kristin L., et al.
Publicado: (2011)

Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A
por: Tanner, Rachel, et al.
Publicado: (2014)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2011)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A
por: Matsumiya, Magali, et al.
Publicado: (2013)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
por: McShane, Helen, et al.
Publicado: (2016)

The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses
por: Tameris, Michele, et al.
Publicado: (2014)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
por: Minassian, Angela M., et al.
Publicado: (2011)

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults
por: Riste, Michael, et al.
Publicado: (2021)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2007)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
por: Pathan, Ansar A., et al.
Publicado: (2011)

Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
por: Tameris, Michele D, et al.
Publicado: (2013)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects
por: Dieye, Tandakha N., et al.
Publicado: (2013)

Towards new TB vaccines
por: Brazier, Benedict, et al.
Publicado: (2020)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
por: Verreck, Frank A. W., et al.
Publicado: (2009)

Progress and challenges in TB vaccine development
por: Voss, Gerald, et al.
Publicado: (2018)

Evaluation of Xpert(®) MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial
por: Bunyasi, Erick Wekesa, et al.
Publicado: (2015)

Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques
por: Verreck, Frank A. W., et al.
Publicado: (2011)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination
por: Bunyasi, E. W., et al.
Publicado: (2017)

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods
por: Rhodes, Sophie J., et al.
Publicado: (2017)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

Aerosol immunisation for TB: matching route of vaccination to route of infection
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2015)

TB vaccine development: where are we and why is it so difficult?
por: Wilkie, Morven E M, et al.
Publicado: (2015)

A review of clinical models for the evaluation of human TB vaccines
por: O'Shea, Matthew K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vnebuf597jqefr0n34685dpej6